In ATL/ATLL, increased plasma galectin-9 level indicates the tumor burden and reflects opportunistic infections resembling the immune reconstitution inflammatory syndrome due to mogamulizumab therapy (144). The gene discussed is LGALS9; the disease is neoplasm.